VSTM241220P18000
- 0.00
- 0.000.00%
Verastem Newsroom
Verastem Inc. Reports Increased Operating Expenses and Net Loss
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
Verastem | 10-Q: Q3 2024 Earnings Report
Express News | Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Express News | Verastem Q3 Basic EPS USD -0.6
Press Release: Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem 3Q Loss/Shr 60c >VSTM
Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Verastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients...
Express News | Verastem Inc - FDA Filing Decision Expected Before End of 2024 With Potential for FDA Approval Decision by Mid-2025
Express News | Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology to Participate in Upcoming Investor Conferences
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Cantor Fitzgerald Reiterates Overweight on Verastem
Verastem (VSTM) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15